A) Antimicrobial Resistance and Antimicrobial Use
1. Molecular and epidemiological basis and impact of antimicrobial use on the unset and dissemintarion of antimicrobial resistance.
Line 1. Antimicrobial Use in animals and foods as transmission vehicle.
Action 1
Effect of the antimicrobials and additives of veterinary use in the unset of resistance to other antimicrobials of human use.
Responsible: Centro Nacional Biotecnología. Dr. Jesús Blázquez .
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Action 2
Animals as reservoir for antimicrobial multi-resistant microorganisms.
Responsible: Universidad de Santiago de Compostela. Dr. Jorge Blanco.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Action 3
Foods as vehicle for multi-resistant bacteria.
Responsible: Hospital Universitario Vall d´Hebron. Dra. Rosa Bartolomé.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Line 2. International Health and resistance dissemination
Action 1
Stays in developing countries, by international travels or immigration as risk for the acquisition .
Responsible: Hospital Universitario Virgen del Rocío. Dr. José Molina.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Line 3. Antimicrobials use and resitance in the community
Action1
Molecular bases of the antimicrobial multi-resitance. Control and prevention strategies.
Responsible: Hospital Universitario Marqués de Valdecilla. Dr. Luis Martínez.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Action 2
Density of antimicrobials use and relation tieh the antimicrobial resistance.
Responsible: Centro Nacional de Microbiología. Dr. José Campos.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Action 3
Optimization of antimicrobial treatment in severe multi-resistant enterobacterias infections.
Responsible: Hospital Universitario Virgen Macarena. Dr. Jesús Rodríguez Baño.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Action 4
Evaluation of control of prevention strategy for the transmission of multi-resistant bacteria in the community.
Responsible: Hospital Universitario Virgen Macarena. Dr. Jesús Rodríguez Baño.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Action 5
Antimicrobial resistance and virulence factor.
Responsible: Universidad de Santiago de Compostela. Dr. Jorge Blanco.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Line 4. Antimicrobials use and resistance in the hospitals and public health centers environment.
Action 1
Molecular and epidemiological bases of the multi-resistance.
Responsible: Complejo Hospitalario Universitario A Coruña. Dr. Germán Bou. This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Action 2
Antimicrobial resistance and virulence factors.
Responsible: Hospital Son Espases
Action 3
Optimization of the use of antimicrobials in the hospitals.
Responsible: Hospital Universitario Virgen Macarena. Dr. Jesús Rodríguez Baño.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Action 4
Interaction of the use of antimicrobials, the expression of tesistance mechanims and bacterial viability.
Responsible: Hospital Universitario Virgen Macarena. Dr. José Manuel Rodríguez.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Action 5
Optimization of antimicrobial empirical treatment of febrile nutropenia.
Responsible: Hospital Universitario Virgen del Rocío. Dr. Manuela Aguilar Guisado.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Action 6
Effect of treatment with piperaciline/tazobactam (PTX) on the serum levels of the galactomanann antigen (AGA).
Responsible: Hospital Universitario Virgen del Rocío. Dr. Manuela Aguilar Guisado.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Action 7
Prevention strategies on the resistance development during the antimicrobial treatment - in vitro and in vivo models.
Responsible: Hospital Universitario Son Espases
Action 8
Optimization of the use of antimicrobials in public health centers.
Responsible: Corporación Sanitaria y Universitaria Parc Taulí. Dr. Anisi Morón.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
/ Dr. Bernat Font.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
2. Development of new antimicrobial agents and no antimicrobial strategies.
Line 1. Development of new antimicrobials against multi-drug resistant gram-neagtive bacilli.
Action 1
Design, optimization and evaluation of new molecules.
Responsible: Hospital Clinic
Action 2
Search for inhibitors for antimicrobial resistance mechanisms.
Responsible: Centro Nacional Biotecnología. Dr. Jesús Blázquez.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Line 2. Development of preventive and therapeutic vaccies and monoclonal antibodies against gram-negative bacilli infections and Staphylococcus aureus.
Action 1
Innate and adaptative reaction to gram-negative bacilli as basis for therapeutic approaches.
Responsable: Hospital Clinic
Action 2
Development of vaccine against Acinetobacter baumannii.
Responsible: Hospital Universitario Virgen del Rocío. Dr. Michael McConnell.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Action 3
Development of vaccines against Escherichia coli.
Responsible: Universidad de Santiago de Compostela. Dr. Jorge Blanco.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Action 4
Development of vaccines against a S. aureus.
Responsible: Hospital Universitario Reina Sofía. Dr. Manuel Rodríguez.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Action 5
Identification os surface proteins of Streptococcus pneumoniae.
Responsible: Hospital Universitario Reina Sofía. Dr. Manuel Rodríguez.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Action 6
Development of monoclonal antibodies for the treatment of gram-negative bacilli infections.
Responsible: Hospital Universitario Virgen del Rocío. Dr. Michael McConnell.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Line 3. Adjuvant treatment in severe infections
Action 1
Study of the efficacy of fenitoin in the prphylaxis of apms in patients over 50 years old affected by prenumococcal meningitis.
Responsible: Hospital Universitario de Bellvitge
3. Desing and evaluation of new strategies and diagnostics for rapid detection of sensitive and resistant bacteria and resitance mechanisms.
Line 1. Rapid diagnostics techniques.
Action 1
Desing, optimization, evaluation and impact on the results in terms of health and cost effectiveness of new rapid diagnostic techniques.
Responsible: Hospital Clinic
Line 2. Rapid techniques for resistance or sensitivity detection and their genetic platforms.
Action 1
Desing, optimization, evaluation and impact on the results in terms of health and cost efectiveness of new techniques for detection of resistance and/or sensitivity.
Responsible: Complejo Hospitalario Universitario A Coruña. Dr. Germán Bou.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
